Fortress Biotech, Inc.
Fortress Biotech, Inc. (Nasdaq: FBIO) is a biopharmaceutical company that acquires and advances drug and other therapeutic assets through subsidiaries and partner companies. It licenses or acquires intellectual property and provides business, scientific, regulatory, legal and financial support, while its companies… From the company’s description.
Over the twelve months to Jun 30, 2026, Fortress Biotech, Inc. reported revenue of $68.47M, up 15.5% from a year earlier, and net income of $141.19M. Its operating margin was −42.6%, and operations generated $125.92M in cash. In fiscal 2025, it reported revenue of $63.26M, up 9.7% from fiscal 2024, and a net loss of $32.91M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fortress Biotech, Inc. does
In the company’s own words
Fortress Biotech, Inc. (Nasdaq: FBIO) is a biopharmaceutical company that acquires and advances drug and other therapeutic assets through subsidiaries and partner companies. It licenses or acquires intellectual property and provides business, scientific, regulatory, legal and financial support, while its companies pursue development, commercialization, partnerships, licensing and financing. Its portfolio includes marketed dermatology products sold through Journey Medical, including Emrosi, Qbrexza, Accutane, Amzeeq and Zilxi, as well as product candidates spanning oncology, gene and cell therapies, rare diseases, infectious disease and pain management. The company also holds interests in assets developed or commercialized by partners, including royalties on sales of UNLOXCYT and ZYCUBO and potential milestone and royalty payments from other programs. Its subsidiaries and partner companies include Journey Medical, Mustang Bio, Avenue Therapeutics, Cellvation, Cyprium Therapeutics, Helocyte, Oncogenuity and Urica Therapeutics. Fortress’s business model includes strategic transactions: Checkpoint Therapeutics was acquired by Sun Pharmaceutical in 2025, and Avenue’s subsidiary Baergic Bio was acquired by Axsome Therapeutics that year.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BAY HARBOR ISLANDS, FL
- Fiscal year end
- December
- CIK
- 1429260
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fortress Biotech, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fortress Biotech, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fortress Biotech, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fortress Biotech, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fortress Biotech, Inc.'s last four quarterly filings that the numbers alone won't show?”